Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …

Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer
immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein …

The T lymphocyte, especially its capacity for antigen-directed cytotoxicity, has become a
central focus for engaging the immune system in the fight against cancer. Basic science …

A major challenge in cancer vaccine therapy is the efficient delivery of antigens and
adjuvants to stimulate a controlled yet robust tumour-specific T-cell response. Here, we …

Tumor microenvironment (TME) cells constitute a vital element of tumor tissue. Increasing
evidence has elucidated their clinicopathologic significance in predicting outcomes and …

Background Advanced recurrent ovarian cancer (ROC) is the leading cause of gynecologic
cancer-related death in developed countries and new treatments are needed. Previous …

Ovarian cancer (OC) is one of the most common gynecologic tumors worldwide and one
with the highest mortality. Cisplatin (DDP) is the first platinum-based complex approved by …

ABSTRACT Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell
checkpoint and plays a central role in regulating T cell exhaustion. Binding of PD-1 to its …

The genomes of cancers deficient in mismatch repair contain exceptionally high numbers of
somatic mutations. In a proof-of-concept study, we previously showed that colorectal cancers …

Treatments that target immune checkpoints, such as the one mediated by programmed cell
death protein 1 (PD-1) and its ligand PD-L1, have been approved for treating human …